Denali Therapeutics Inc.

NASDAQ: DNLI · Real-Time Price · USD
14.71
0.25 (1.73%)
At close: Aug 15, 2025, 3:59 PM
15.73
6.97%
After-hours: Aug 15, 2025, 06:45 PM EDT

Denali Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a 330.53M 108.46M 48.66M
Cost of Revenue
n/a 16.73M 7.03M 5.61M
Gross Profit
n/a 313.81M 101.43M 43.05M
Operating Income
-487.34M -196.7M -340.74M -295.75M
Interest Income
n/a 51.51M 14.77M 4.59M
Pretax Income
-422.7M -145.19M -325.97M -291.16M
Net Income
-422.77M -145.22M -325.99M -290.58M
Selling & General & Admin
105.44M 103.35M 90.47M 79.06M
Research & Development
396.44M 423.88M 358.73M 265.35M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
501.88M 527.23M 449.21M 344.41M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
n/a 527.23M 449.21M 344.41M
Income Tax Expense
68K 30K 21K -575K
Shares Outstanding (Basic)
164.47M 137.37M 125.53M 121.52M
Shares Outstanding (Diluted)
164.47M 137.37M 125.53M 121.52M
EPS (Basic)
-2.57 -1.06 -2.6 -2.39
EPS (Diluted)
-2.57 -1.06 -2.6 -2.39
EBITDA
-414.91M -179.97M -330.36M -287.16M
EBIT
-422.7M -196.7M -340.74M -295.75M
Depreciation & Amortization
7.79M 16.73M 7.03M 5.61M